The estimated Net Worth of Rhonda Farnum is at least $3.33 Millón dollars as of 10 July 2024. Ms Farnum owns over 4,000 units of Theravance Biopharma Inc stock worth over $2,721,317 and over the last 3 years she sold TBPH stock worth over $172,527. In addition, she makes $435,518 as Chief Bus. Officer and Sr. VP of Commercial & Medical Affairs at Theravance Biopharma Inc.
Ms has made over 8 trades of the Theravance Biopharma Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently she sold 4,000 units of TBPH stock worth $36,000 on 10 July 2024.
The largest trade she's ever made was selling 4,000 units of Theravance Biopharma Inc stock on 10 July 2024 worth over $36,000. On average, Ms trades about 930 units every 45 days since 2021. As of 10 July 2024 she still owns at least 335,965 units of Theravance Biopharma Inc stock.
You can see the complete history of Ms Farnum stock trades at the bottom of the page.
Rhonda F. Farnum is the Chief Bus. Officer and Sr. VP of Commercial & Medical Affairs at Theravance Biopharma Inc.
As the Chief Bus. Officer and Sr. VP of Commercial & Medical Affairs of Theravance Biopharma Inc, the total compensation of Ms Farnum at Theravance Biopharma Inc is $435,518. There are 10 executives at Theravance Biopharma Inc getting paid more, with Rick Winningham having the highest compensation of $5,932,410.
Ms Farnum is 56, she's been the Chief Bus. Officer and Sr. VP of Commercial & Medical Affairs of Theravance Biopharma Inc since . There are 15 older and 11 younger executives at Theravance Biopharma Inc. The oldest executive at Theravance Biopharma Inc is Burton Malkiel, 87, who is the Independent Director.
Rhonda's mailing address filed with the SEC is C/O THERAVANCE BIOPHARMA US, INC., 901 GATEWAY BLVD, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 11 years, insiders at Theravance Biopharma Inc have traded over $11,619,559 worth of Theravance Biopharma Inc stock and bought 4,008,513 units worth $29,986,832,769,275 . The most active insiders traders include Plc Gsk, Inc. Innoviva, y Eli Samaha. On average, Theravance Biopharma Inc executives and independent directors trade stock every 57 days with the average trade being worth of $448,635. The most recent stock trade was executed by Eli Samaha on 7 August 2024, trading 999,800 units of TBPH stock currently worth $7,798,440.
theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.
Theravance Biopharma Inc executives and other stock owners filed with the SEC include: